Danaher posted a strong Q3 beat on revenue and EPS, with bioprocessing consumables driving high single-digit core growth and diagnostics benefiting from early-season respiratory demand. Management provided an initial 2026 guide of 3-6% core growth and high single-digit EPS expansion, supported by cost actions and margin improvement, while noting equipment orders remain soft due to policy uncertainty. Q3 sales $6.1B (core +3%), adj EPS $1.89 (+10% YoY), FCF $1.4B, beat expectations.
Danaher posted a strong Q3 beat on revenue and EPS, with bioprocessing consumables driving high single-digit core growth and diagnostics benefiting from early-season respiratory demand. Management provided an initial 2026 guide of 3-6% core growth and high single-digit EPS expansion, supported by cost actions and margin improvement, while noting equipment orders remain soft due to policy uncertainty. Q3 sales $6.1B (core +3%), adj EPS $1.89 (+10% YoY), FCF $1.4B, beat expectations.
Management expressed confidence in execution and long-term growth but maintained a cautious stance on near-term market recovery, guiding to modest improvements and not baking in order inflections.
Guidance · revenue to 4.5%
Guidance · revenue to 4.5%
Bioprocessing consumables grew double digits, equipment declined high teens. Management expressed confidence in execution and long-term growth but maintained a cautious stance on near-term market recovery, guiding to modest improvements and not baking in order inflections.
Management mentioned accelerating digital and artificial intelligence initiatives as part of investments to strengthen the long-term competitive position, but provided no specific financial or product details.
Bioprocessing consumables grew double digits, equipment declined high teens. Management expressed confidence in execution and long-term growth but maintained a cautious stance on near-term market recovery, guiding to modest improvements and not baking in order inflections.
Management noted several billions of dollars have been invested to expand capacity at Cytiva since 2020, including facilities in Florida, South Carolina, Utah, and Michigan, positioning the company for in-region manufacturing strategies. They also mentioned taking actions to reduce structural costs, with $175 million in productivity investments planned for 2025 generating $75 million in net saving
Management expressed confidence in execution and long-term growth but maintained a cautious stance on near-term market recovery, guiding to modest improvements and not baking in order inflections.
“we have seen increased development of biosimilars and expanded indications for existing therapies, both of which are expected to drive production volume growth.”
“I would say it was probably 125 million of pull forward if you want to call it that, but it was nothing else to call out.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2025 | $7.70–$7.80 | $7.75 | MAINTAINED |
| Revenue | FY2026 | 3%–6% | 4.5% | GUIDED |
| RevenueRESPIRATORY | FY2026 | $1.7B | $1.7B | GUIDED |
| 제시 시점 | 지표 | 목표 기간 | 가이던스 | 실제 | 결과 |
|---|---|---|---|---|---|
| FY2026 Q1 | Op margin | FY2026 Q2 | 26.5% | 17.99% | Missed |
| FY2025 Q4 | Op margin | FY2026 Q1 | 28.5% | 22.58% | Missed |